GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Cash Receipts from Tax Refunds

Mersana Therapeutics (STU:0M4) Cash Receipts from Tax Refunds


View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Cash Receipts from Tax Refunds?

Cash Receipts from Tax Refunds only applicable to companies reporting Cash Flow from Operations in direct method.


Mersana Therapeutics (STU:0M4) Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.